VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

M-M-R II Meruvax II ProQuad
Vaccine Information Vaccine Information Vaccine Information
  • Product Name: Measles, Mumps, and Rubella Virus Vaccine, Live
  • Tradename: M-M-R II
  • Manufacturer: Merck & Co., Inc.
  • Vaccine Ontology ID: VO_0000069
  • CDC CVX code: 03
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA(License #0002)
  • Host Species for Licensed Use: Human
  • Preparation: The growth medium for rubella is Minimum Essential Medium (MEM) [a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum] containing recombinant human albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests (FDA: MMR-II).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: 2 to 8°C (36 to 46°F) or colder. Do not freeze.
  • Approved Age for Licensed Use: 12 months or older
  • Contraindication: Hypersensitivity to any component of the vaccine, a history of anaphylactic or anaphylactoid reactions to neomycin (FDA: MMR-II).
  • Description: M-M-R II is a sterile lyophilized preparation of (1) ATTENUVAX* (Measles Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) MUMPSVAX* (Mumps Virus Vaccine Live), the Jeryl Lynn** (B level) strain of mumps virus propagated in chick embryo cell culture; and (3) MERUVAX* II (Rubella Virus Vaccine Live), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts (FDA: MMR-II).
  • Product Name: Rubella Virus Vaccine Live
  • Tradename: Meruvax II
  • Manufacturer: Merck & Co., Inc.
  • Vaccine Ontology ID: VO_0000073
  • CDC CVX code: 06
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA (License #0002)
  • Host Species for Licensed Use: Human
  • Antigen: Wistar Institute RA 27/3 strain of live attenuated rubella virus
  • Preparation: MERUVAX II is a sterile lyophilized preparation of the Wistar Institute RA 27/3 strain of live attenuated rubella virus. The virus was adapted to and propagated in WI-38 human diploid lung fibroblasts. The growth medium is Minimum Essential Medium (MEM) containing human serum albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests. The cells, virus pools, fetal bovine serum, and human albumin are all screened for the absence of adventitious agents. Human albumin is processed using the Cohn cold ethanol fractionation procedure. The product contains no preservative (FDA: Meruvax II).
  • Immunization Route: Intradermal injection (i.d.)
  • Storage: The vaccine must be maintained at a temperature of 10°C (50°F) or colder.
  • Approved Age for Licensed Use: 6-15 months is the recommended age
  • Contraindication: Hypersensitivity to any component of the vaccine, including gelatin, and anaphylactic or anaphylactoid reactions to neomycin (FDA: Meruvax II).
  • Description: MERUVAX* II (Rubella Virus Vaccine Live) is a live virus vaccine for vaccination against rubella (German measles) (FDA: Meruvax II) .
  • Product Name: Measles, Mumps, Rubella and Varicella Virus Vaccine Live
  • Tradename: ProQuad
  • Manufacturer: Merck & Co, Inc.
  • Vaccine Ontology ID: VO_0000091
  • CDC CVX code: 94
  • Type: Live, attenuated vaccine
  • Status: Licensed
  • Location Licensed: USA (License #0002)
  • Host Species for Licensed Use: Human
  • Preparation: propagated in WI-38 human diploid lung fibroblasts (FDA: Proquad).
  • Immunization Route: Intramuscular injection (i.m.)
  • Storage: 2° to 8°C (36° to 46°F) or colder.
  • Approved Age for Licensed Use: 12 months to 12 years old
  • Contraindication: Vaccine should not be administered to anyone with a known history of anaphylactic reactions to neomycin, or to anyone with a history of hypersensitivity to gelatin or any other component of the vaccine (FDA: Proquad).
  • Description: ProQuad is a sterile lyophilized preparation of (1) the components of M-M-R*II (Measles, Mumps and Rubella Virus Vaccine Live): Measles Virus Vaccine Live, a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; Mumps Virus Vaccine Live, the Jeryl Lynn™ (B level) strain of mumps virus propagated in chick embryo cell culture; Rubella Virus Vaccine Live, the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts; and (2) Varicella Virus Vaccine Live (Oka/Merck) refrigerator-stable formulation, the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 cells (FDA: Proquad).
Host Response Host Response Host Response

Human Response

  • Immune Response: Neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in most individuals 11 to 13 years after primary vaccination (FDA: MMR-II).
  • Side Effects: Side effects of vaccination are: fever, headache, dizziness, and irritability.
  • Efficacy: Many clinical studies have shown the vaccine have a high rate of efficacy protection after vaccination with MMR-II (FDA: MMR-II).

Human Response

  • Vaccination Protocol: Clinical studies have been carried out in more than 28,000 human subjects (approximately 11,000 with MERUVAX II) in the United States and more than 20 additional countries (FDA: Meruvax II).
  • Immune Response: A single injection of the vaccine has been shown to induce rubella hemagglutination-inhibition (HI) antibodies in 97% or more of susceptible persons.
  • Side Effects: Side effects of vaccination include: fever, headache, dizziness, and itching, redness or swelling of the injection site.
  • Efficacy: Clinical studies helped to establish that seroconversion in response to rubella vaccination paralleled protection from this disease.

Human Response

  • Immune Response: According to clinical trials, there were high levels of antibodies in 99.6% of those vaccinated after a single dose of Proquad (FDA: Proquad).
  • Side Effects: Side effects of vaccination include: injection site reactions, fever, irritability and diarrhea.
References References References
FDA: MMR-II: FDA: MMR-II Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094050.htm]
FDA: Meruvax II: FDA: Meruvax II vaccine information [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094064.htm]
FDA: Proquad: FDA: Proquad Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm188806.htm]